Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck

The goal of this clinical trial is to learn if the combination of the drug cemiplimab along with a short course of radiation therapy called Quad Shot can be successfully given in several rounds to elderly or frail patients with head and neck skin cancers. The main question it aims to answer is: \- Can care providers successfully deliver at least 6 rounds of cemiplimab and 3 rounds of Quad Shot radiation to patients? Patients will: * Be given cemiplimab every 3 weeks for a total of up to 8 doses * Be given Quad Shot radiation (four treatments over two days) every 3 weeks for a total of up to

Trial Details

NCT ID
NCT07869823
Phase
EARLY_PHASE1
Sponsor
Vanderbilt-Ingram Cancer Center
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Cemiplimab
  • Radiation Therapy
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Locally advanced squamous cell carcinoma of the skin arising from the head and neck region.
  • Patients who have had prior treatment of a localized skin primary and now present with nodal recurrence or unresectable local recurrence are consid…
  • No prior systemic therapy including chemotherapy, targeted therapy or immunotherapy.
  • Deemed unfit for definitive curative intent treatment with surgery or radiation therapy due to one of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →